ORIC Pharmaceuticals to Attend June 2024 Investor Conferences

ORIC Pharmaceuticals, Inc., a company specializing in oncology and focused on combating therapeutic resistance, has announced its participation in two upcoming investor conferences in June. The company, listed on Nasdaq under the symbol ORIC, is set to engage in discussions at these events, providing insights into its ongoing projects and progress.

On June 5, 2024, at 10:30 a.m. ET, ORIC will be represented at the Jefferies Global Healthcare Conference through a fireside chat. This will be followed by another fireside chat on June 10, 2024, at 10:40 a.m. ET, during the Goldman Sachs 45th Annual Global Healthcare Conference. These sessions will be accessible via webcasts through the investor section of ORIC’s website, and replays will be available for 90 days after the events.

ORIC Pharmaceuticals is engaged in the development of innovative treatments aimed at overcoming resistance in cancer therapy. The company’s leading clinical-stage product candidates include:

1. ORIC-114: This is a brain-penetrant inhibitor that selectively targets the EGFR and HER2 receptors, showing high potency against exon 20 insertion mutations. This candidate is being tested across a range of genetically defined cancers.

2. ORIC-944: An allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, ORIC-944 is being developed for the treatment of prostate cancer.

3. ORIC-533: This is an orally bioavailable small molecule inhibitor of CD73, which is a crucial component in the adenosine pathway. CD73's role in resistance to chemotherapy and immunotherapy makes it a significant target in the treatment of multiple myeloma.

In addition to these three candidates, ORIC is also working on several precision medicines targeting various mechanisms of cancer resistance. These efforts reflect the company’s commitment to improving cancer treatment by addressing the fundamental issues that cause therapeutic resistance.

The company’s operations are based out of two offices located in South San Francisco and San Diego, California. 

As ORIC continues its mission to advance cancer treatments, the upcoming conferences will provide valuable opportunities for the company to share its progress and engage with the investment community.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!